Market Overview

UPDATE: Jefferies Raises PT on Abbott Laboratories on Attractive Valuation

Share:
Related ABT
Stocks Hitting 52-Week Highs
Earnings Scheduled For July 22, 2015
Merck Tops on Q2 Earnings & Revenues, Revises Outlook - Analyst Blog (Zacks)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $40.00 to $42.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Abbott Laboratories closed on Tuesday at $36.55.

Latest Ratings for ABT

DateFirmActionFromTo
Jul 2015BarclaysMaintainsEqual-weight
Jul 2015BMO CapitalMaintainsOutperform
Jul 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

Get Benzinga's Newsletters